ArticleJournal of human immunity2026
Clinical, genetic, and immunologic features of APS-1 patients from the Middle East, and a review of the literature.
Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune polyglandular syndrome type-1 (APS-1) results from mutations in autoimmune regulator (AIRE), a transcription factor that drives thymic expression of tissue-restricted antigens, thus enabling deletion of self-reactive thymocytes to maintain tolerance. APS-1 typically manifests with hypoparathyroidism, adrenal insufficiency, and candidiasis, but presentation varies. In this study, we characterized the clinical, genetic, and immunologic features of 18 new APS-1 patients and reviewed all reported cases to identify additional manifestations and mutational hotspots useful for targeted sequencing. We report three previously unpublished mutations, reduced T cell function, and diminished Treg numbers in our patients. Furthermore, we identified alopecia, thyroid disease, and diabetes mellitus as additional diagnostic clues, and revealed five recurrent variants that account for over 80% of known mutations. Our findings highlight additional clinical and laboratory features and emphasize key mutational hotspots that can accelerate the diagnosis to improve the timely and cost-effective identification of APS-1, especially in settings with limited awareness or resources.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.